• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

    7.620 -0.320 (-4.03%)
    Streaming Delayed Price Updated: 11:29 AM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about ARS Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    News headline image
    BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. ↗
    Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
    Via Investor's Business Daily
    News headline image
    ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 13, 2024 ↗
     
    Via Benzinga
    News headline image
    Insights Ahead: ARS Pharmaceuticals's Quarterly Earnings ↗
     
    Via Benzinga
    News headline image
    Where ARS Pharmaceuticals Stands With Analysts ↗
     
    Via Benzinga
    News headline image
    Analyst Ratings For ARS Pharmaceuticals ↗
     
    Via Benzinga
    News headline image
    ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia
    Licensing partners in key Asia Pacific countries have filed for approval of neffy (epinephrine nasal spray) 2 mg with regulatory agencies 
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Looking Into ARS Pharmaceuticals's Recent Short Interest ↗
     
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharma Jumps After Inking $145 Million Deal For Epinephrine Nasal Spray ↗
    Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it. 
    Via Investor's Business Daily
    News headline image
    ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024 ↗
    ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment. 
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces Conference Call and Webcasts for its Third Quarter 2024 Financial Results and Presentations at Upcoming Conferences
    Third Quarter Earnings Conference Call to be Held on November 13 at 8:00 a.m. ET 
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect 
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Newly Approved ARS Pharmaceuticals' Needle-Free Neffy Offers Convenience Over EpiPen For Allergic Reaction, But Real-World Efficacy Questioned ↗
    Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles. 
    Via Benzinga
    News headline image
    ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst ↗
    "FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and... 
    Via Benzinga
    News headline image
    Fabrinet Posts Strong Earnings, Joins Amer Sports, Hawaiian Holdings And Other Big Stocks Moving Higher On Tuesday ↗
     
    Via Benzinga
    News headline image
    Loar Holdings Posts Upbeat Results, Joins Nvidia, Clean Energy Fuels, Penumbra And Other Big Stocks Moving Higher On Tuesday ↗
     
    Via Benzinga
    News headline image
    FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment ↗
    FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,... 
    Via Benzinga
    News headline image
    ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference
    From ARS Pharmaceuticals, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.